AstraZeneca shot at 79 percent efficiency in tests in the United States, Chile and Peru | Coronavirus pandemic News
The data paves the way for the company, which has been implicated in an EU security line, to seek US approval for its COVID-19 jab.
AstraZeneca claims the COVID-19 vaccine it developed in cooperation with the University of Oxford was 79% effective in preventing symptomatic illness, a large trial in the United States, Chile and Peru leading the way at his long-awaited request for US approval.
The vaccine was found to be 100% effective against serious or critical illnesses and hospitalizations and was safe, the drugmaker said on Monday, as it released the results of the human trial study at an advanced stage of over 32,000 volunteers from all age groups.
The study found the vaccine to be effective at all ages, including the elderly, about which previous studies in other countries had raised concerns.
Although AstraZeneca’s vaccine has been licensed in more than 50 countries, it has yet to be given the green light in the United States.
It will also help allay safety concerns that disrupted its use in the European Union after a small number of cases of rare blood clots in people who received the injection were reported.
After more than two dozen countries briefly halted its use, many European countries resumed using the vaccine in their immunization programs after a regional regulator declared it safe, while several country leaders also take the vaccine to build confidence.
“No increased risk” of blood clots
AstraZeneca said that an independent safety committee performed a specific examination for blood clots in the US trial, as well as cerebral venous sinus thrombosis (CVST), which is an extremely rare blood clot in the brain, with l help from an independent neurologist.
The London-listed company said the panel found “no increased risk of thrombosis [the process of a blood clot forming] or events characterized by thrombosis among the 21,583 participants receiving at least one dose of the vaccine. The specific search for CVST did not find any events in this trial ”.
The data will be prepared to seek approval from the U.S. Food and Drug Administration (FDA), Oxford University professor Sarah Gilbert told BBC radio. Preparation will take a few weeks, she added.
The United States has ordered 300 million doses of the vaccine and has come under pressure to share the doses manufactured in the country before FDA approval.
The White House said last week that the United States currently has 7 million “releasable doses” of the vaccine and is in the process of making deals to “loan” 2.5 million doses to Mexico and 1 , 5 million doses in Canada in the near future.